Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.

Theresa A Guise1, Khalid S Mohammad, Gregory Clines

  • 1Department of Medicine, University of Virginia, Charlottesville, Virginia 22903, USA. tag4n@virginia.edu

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|October 26, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systematic analysis of hippo pathway signaling identifies TEAD1 as a transcriptional regulator of neuroendocrine prostate cancer.

Neoplasia (New York, N.Y.)·2026
Same author

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer.

Molecular cancer research : MCR·2026
Same author

TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens.

EMBO molecular medicine·2026
Same author

Therapeutic targeting of the eIF4E cap-binding domain reveals control of lineage fate in prostate cancer.

The Journal of clinical investigation·2026
Same author

Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity.

The Journal of clinical investigation·2026
Same author

FOXJ1 mediates taxane resistance through regulation of microtubule dynamics.

Nature communications·2026

Solid tumors can spread to bone, causing both bone destruction (osteolysis) and new bone formation (osteoblastic metastases). Understanding these complex mechanisms is key to developing new treatments for bone metastases.

Area of Science:

  • Oncology
  • Orthopedics
  • Cell Biology

Background:

  • Solid tumors frequently metastasize to bone.
  • Bone metastases manifest as osteolytic (bone destruction) or osteoblastic (new bone formation) lesions, often co-existing in patients.
  • Tumor growth in bone involves complex interactions between tumor cells, osteoclasts, osteoblasts, and the bone microenvironment.

Purpose of the Study:

  • To discuss the mechanisms underlying osteolytic and osteoblastic bone metastases.
  • To explore the therapeutic implications of these mechanisms.

Main Methods:

  • Review of existing literature on bone metastasis.
  • Analysis of cellular and molecular mechanisms driving bone remodeling in the context of cancer.
  • Discussion of factors influencing the tumor-bone interaction.

Related Experiment Videos

Main Results:

  • Bone metastases represent a spectrum of osteolysis and osteoblastic activity.
  • Tumor cells directly and indirectly stimulate bone cells (osteoclasts and osteoblasts).
  • The bone microenvironment plays a critical role in supporting tumor growth.
  • Extragonadal factors like sex steroid deficiency can exacerbate bone metastases.

Conclusions:

  • Effective treatment of bone metastases requires targeting the complex interplay between tumor cells and the bone microenvironment.
  • Therapeutic strategies should address both osteolytic and osteoblastic processes.
  • Further research into the mechanisms of tumor growth in bone is crucial for improved patient outcomes.